Wuhan General Group China Announces Corporate Update

May 17, 2022 5:15 PM

CAPE TOWN, SA / ACCESSWIRE / May 17, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:M2Bio Sciences is pleased to announce that an approach has been received from an unrelated arms length third party to acquire all the operating subsidiaries of Wuhan General Group...

Read more

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

May 17, 2022 12:00 PM

HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor cell-derived nanotherapeutics and scalable biomanufacturing process.The MSA enables EV Biologics to accelerate its nanotherapeutic biomanufacturing process and producer-cell line development through Lonza's global infrastructure and deep expertise in...

Read more

Black Bird Biotech Announces MiteXstream Honey Bee Contact Toxicity Study Final Report: Not Toxic to Honey Bees

May 17, 2022 8:31 AM

FLOWER MOUND, TX / ACCESSWIRE / May 17, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that, an independent lab testing, MiteXstreamTM was proven to be "NOT TOXIC" to honey bees when contacted topically by the biopesticide.Performing Lab: STILLMEADOW, Inc., Sugar Land, Texas.Study Director: Cole Younger, PhD., Entomologist, STILLMEADOW, Inc.The Study: MiteXstream: Honey...

Read more

International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022

May 17, 2022 6:00 AM

SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and financial results for the three months ended March 31, 2022."I would like to highlight the fact that our business units are steadily...

Read more

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 16, 2022 4:05 PM

Dermata completes a $5.0 million private placement financingDMT310 Phase 2 rosacea trial topline results expected in H2 2022SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress and reported financial results for the quarter ended...

Read more

Black Bird Biotech President Interviewed By Market Research Firm PubCo Insight

May 16, 2022 8:30 AM

FLOWER MOUND, TX / ACCESSWIRE / May 16, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today reported that a recent interview of President, Fabian Deneault, by PubCo Insight has been released.Mr. Deneault's interview can be viewed here, as well as on social media: @BBBT_Corporate on Twitter; @BlackBirdBiotech on Instagram; and BlackBirdBiotech on Facebook, where viewers are able to join the...

Read more

Hemogenyx Pharmaceuticals PLC Announces Immuno-Oncology Summit Europe Presentation

May 16, 2022 2:00 AM

LONDON, UK / ACCESSWIRE / May 16, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce its participation in the Immuno-Oncology Summit Europe 2022, at which Dr Vladislav Sandler will make a presentation entitled "Anti-FLT3 CAR-T and Bispecific Antibody Therapies for Effective Elimination of AML and Conditioning for Hematopoietic Stem Cell Transplantation". The conference assembles a wide range of thought leaders from both...

Read more

Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

May 13, 2022 8:55 AM

TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2022 and provided an update on its business.For its critical care drug candidate, Edesa reported during the quarter that more than 25% of the subjects have been randomized for the Phase 3 part of...

Read more

Artelo Biosciences to Present at MicroCap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th

May 13, 2022 8:30 AM

SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held...

Read more

ONT Chosen for Comprehensive Human Genome Program

May 13, 2022 2:00 AM

Oxford Nanopore sequencing selected to generate comprehensive insights by characterising a more complete genome using samples from the 1000 Genomes ProjectOxford Nanopore technology will enable the 1000 Genomes Project, spearheaded by researchers at the University of Washington and Seattle Children's Hospital, to gain greater genomic insights into clinically relevant variants by providing accurate, affordable, scalable and comprehensive...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022 4:05 PM

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities- DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications- Focusing resources on advancing DNase based oncology platform in locally advanced or metastatic solid tumors towards Phase 1 clinical development- Ended the...

Read more

iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022

May 12, 2022 3:30 PM

NASHUA, NH / ACCESSWIRE / May 12, 2022 / iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually on May 16th - 20th, 2022.Stacey Stevens, President and CEO of iCAD, Inc. will present on Tuesday, May 17, 2022, from 11:30 to 11:55 a.m. EST. iCAD...

Read more

Health Canada Approves Cube Psytech’s Controlled Substance License Application

May 12, 2022 1:05 PM

VANCOUVER, BC / ACCESSWIRE / May 12, 2022 / Cube Psytech Inc. (the "Company" or " CUBE"), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is pleased to announce the approval of the company's application to Health Canada to use restricted drugs for scientific purposes, the following authorization is being granted to...

Read more

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022 7:00 AM

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDTBOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the first quarter of 2022 ended March 31, 2022, and provided...

Read more

ITOCO acquires Colorful Euphoria, Lda to launch its "Soil Rescue Program" in Europe and Africa

May 10, 2022 1:15 PM

TORONTO, ON / ACCESSWIRE / May 10, 2022 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce it has acquired 49 % of Colorful Euphoria, Lda.Colorful Euphoria, Lda is a Portuguese company that operates via joint venture 100 hectares of farm land in the Alentejo region of Portugal. Itoco intends to expand this land position and create an Agro Park focused on advancing a "Soil Rescue Program".Nopal Cactus are being grown effectively and profitably...

Read more

Black Bird Biotech Updates State Registrations of MiteXstream Biopesticide and Announces Recent Onboarding of Sales V.P. and Amazon(R) Store Launch

May 10, 2022 8:45 AM

FLOWER MOUND, TX / ACCESSWIRE / May 10, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today reported that it has now gained registration of its MiteXstreamTM biopesticide in 43 states and in D.C. Applications have been pending since last Fall in six of the remaining states, with the application for California registration nearing completion.BBBT also announced the recent appointment of...

Read more

Biobohemia Pushes Forward Antigenic Essence Technology in Released Paper

May 10, 2022 8:00 AM

CAMBRIDGE, MA / ACCESSWIRE / May 10, 2022 / Biobohemia's scientists share in a released paper ("Changing Landscape of Cancer Vaccines-Novel Proteomics Platform for New Antigen Compositions") the experience gained over the past year in advancing antigen essence technology, including that related to relationships with contract manufacturing organizations, the upgrading of existing experimental cancer vaccines, and the legal and ethical aspects of...

Read more

Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development

May 9, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to execute its next phase with Connect2Trials, Inc. Originally, the Company engaged with Ribera Solutions, Inc.'s "Connect2Med" on its patient engagement platform for clinical trials. Ribera has diligently worked on advancing its technology and engagement with pharma and biotech companies with the support of...

Read more

Biovica's DiviTum(R)TKa at ASCO

May 9, 2022 7:30 AM

UPPSALA, SWEDEN / ACCESSWIRE / May 9, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)Biovica, active in cancer diagnostics, today announces that the company's blood test DiviTum®TKa will be included in one oral presentation and two abstracts/posters, at the world's largest cancer congress, ASCO Annual Meeting, June 3-7, 2022, in Chicago, USA.Results from BioItaLEE, an Italian multicenter study of metastatic BC, CDK4/6...

Read more

Ensysce Biosciences Releases 2021 Annual Shareholder Letter

May 5, 2022 5:15 PM

SAN DIEGO, CA / ACCESSWIRE / May 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the release of its 2021 Annual Shareholder Letter authored by Chief Executive Officer, Dr. Lynn Kirkpatrick. To view the letter...

Read more